Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets
Merck & Co., Inc. (NYSE: MRK) is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life after its 2028 patent cliff. As of early afternoon on December 2, 2025, Merck shares trade around $101 (roughly $100.8–$101.0, down about 1% on the day), giving the company a market cap in the $250+ billion range. The stock sits not far below its recent 52‑week high of $105.84, after a powerful rally in November that lifted Merck more than